Parexel Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey

Company recognized for service provider leadership
among global customers 

Also named a 2019 CRO Leadership Award Winner

BOSTON, April 2, 2019 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced it has been ranked #1 among global Clinical Research Organizations (CROs) for service provider leadership in Phase II/III clinical research according to a global survey of pharmaceutical and biotechnology companies by Industry Standard Research (ISR). As a result of the survey, which assessed 60 CROs on 20+ performance metrics, PAREXEL also was named the recipient of a 2019 CRO Leadership Award from Life Science Leader magazine for meeting or exceeding customer expectations across six different categories.

ISR’s report, titled “CRO Quality Benchmarking – Phase II/III Service Providers (11th Edition),” surveyed 290 biopharmaceutical professionals across North America, Europe and Asia. In addition to ranking #1 for service provider leadership with 67 percent of respondents recognizing PAREXEL in this category, the company also received recognition for:   

  • Highest customer loyalty score and only large provider to top the list for the category
  • Lowest staff turnover among large providers
  • Among the top performers in patient recruitment and study monitoring
  • Highest brand index score based on awareness, familiarity and leadership

“Phase II and III clinical research are critical steps along the drug development journey and PAREXEL’s focus first and foremost is on quality execution to expedite the delivery of important new therapies to the patients who need them,” notes Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer, PAREXEL. “We are proud of our 20,000 employees worldwide whose passion for making a difference in patients’ lives and commitment to our customers has resulted in this recognition. We look forward to continuing to build on our strong track record of advancing new therapies efficiently and effectively.”

PAREXEL received a 2019 CRO Leadership Award from Life Science Leader for meeting or exceeding customer expectations across six categories including Capabilities, Compatibility, Expertise, Phase IV, Quality and Reliability, which are measured based on a subset of report data. This is the eighth consecutive time PAREXEL has received this award.

Over the past five years, PAREXEL has supported 5,260 Phase II and Phase III studies in 14 therapeutic areas. For more information on PAREXEL’s Phase II/III services, visit

About PAREXEL International

PAREXEL International Corporation is a leading innovator of global biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL helps to develop innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit our website and follow us on LinkedIn
 and Twitter.

PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners.


# # #


PAREXEL Contacts:

Wendy Ryan
Tel.: +1 781-434-5104

Kathryn McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300

We are always available for a conversation.


We are always available for a conversation.


Communication Preference

Communication Preference